证券代码：300702 证券简称：天宇股份 公告编号：2023-046 浙江天宇药业股份有限公司 关于 2023 年半年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）于 2023 年 8 月 28 日召开 第五届董事会第二次会议和第五届监事会二次会议，分别审议通过了《关于 2023 年半年度计提资产减值准备的议案》。根据相关规定，本次计提资产减值准备事 项无需提交公司股东大会审议。现将公司 2023 年半年度计提资产减值准备的具 体情况公告如下： 一、本次计提资产减值准备的情况概述 根据《企业会计准则》、《深圳证券交易所上市公司自律监管指引第 2 号— 创业板上市公司规范运作》及公司会计政策等相关要求，为更加真实、准确反映 公司截至 2023 年 6 月 30 日的财务状况及经营成果，基于谨慎性原则，公司及合 并范围内子公司对 2023 年 6 月 30 日的应收账款、其他应收款、存货、长期股权 投资、固定资产、在建工程、无形资产等资产进行了减值测试，对 ...

2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》以及公司《募集资金管理办法》 等有关规定，现将浙江天宇药业股份有限公司（以下简称"公司"或"天宇股份"） 2023 年半年度募集资金存放与使用情况报告如下： 证券代码：300702 证券简称：天宇股份 公告编号：2023-045 浙江天宇药业股份有限公司 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 2020 年向特定对象发行股票募集资金情况 经中国证券监督管理委员会证监许可〔2020〕2842 号文核准，并经深圳证券 交易所同意，本公司由主承销商中信建投证券股份有限公司采用代销方式，向特 定对象发行人民币普通股（A 股）股票 11,117,974 股，发行价为每股人民币 80.95 元，共计募集资金 899,999,995.30 元，坐扣承销和保荐费用 4 ...

4、问：今年公司业务增长点主要在哪里？ 答：公司本年度业务增长点主要有以下几个方面： （1）公司将继续加强市场开发团队规模和能力，开拓其他非沙 坦类原料药的全球销售市场，不断提升原料药全球销售市场占 有率。 股票代码：300702 股票简称：天宇股份 浙江天宇药业股份有限公司 投资者关系活动记录表 编号：2023-003 | 投资者关系活动类别 | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 √业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及人员 | 线上参与公司天宇股份 年度网上业绩说明会的投资者 2022 | | 姓名 | | | 时间 | 2023 年 05 月 10 日（星期三）下午 15:30-17:00 | | 地点 | "天宇股份投资者关系"微信小程序 | | 上市公司接待人员姓 | 董事长兼总经理：屠勇军先生 | | 名 | 董事会秘书兼副总经理：王艳女士 | | | 财务总监：王秀娟女士 | | | 独立董事：张国昀先生 | | | 保荐代表人：黄建飞先生 1 ...

证券代码：300702 证券简称：天宇股份 公告编号：2023-029 浙江天宇药业股份有限公司 关于召开 2022 年度网上业绩说明会的公告 出席本次网上说明会的人员有：董事长兼总经理屠勇军先生，董事会秘书兼 副总经理王艳女士，财务总监王秀娟女士，独立董事张国昀先生，保荐代表人黄 建飞先生。 1 / 2 敬请广大投资者积极参与。 特此公告。 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）已于 2023 年 04 月 27 日 在巨潮资讯网（http://www.cninfo.com.cn/）上披露了《天宇股份 2022 年年度报告》。 为便于广大投资者进一步了解公司 2022 年年度经营情况，公司定于 2023 年 5 月 10 日（星期三）下午 15:30 至 17:00 时在"天宇股份投资者关系"小程序举 行 2022 年度网上业绩说明会。本次网上业绩说明会将采用网络远程的方式举行， 投资者可登陆"天宇股份投资者关系"小程序参与互动交流。为广泛听取投资者 的意见和建议，提前 ...

Financial Performance - The company's revenue for Q1 2023 was ¥777,213,687.73, representing a 3.64% increase compared to ¥749,897,751.64 in the same period last year[5] - Net profit attributable to shareholders was ¥100,237,944.26, an increase of 18.31% from ¥84,721,433.74 year-on-year[5] - The net profit excluding non-recurring gains and losses was ¥91,674,717.31, reflecting a significant increase of 36.92% compared to ¥66,953,384.56 in the previous year[5] - The basic earnings per share rose to ¥0.2901, up 19.14% from ¥0.2435 in the same period last year[5] - The company reported a net profit margin of 16.5% for Q1 2023, compared to 14.5% in Q1 2022[21] - Operating profit reached CNY 127,168,082.73, up from CNY 99,450,209.38, indicating a growth of 28.0% year-over-year[22] - The company reported a total comprehensive income of CNY 100,237,944.26, compared to CNY 84,721,433.74 in the previous year, indicating a growth of 18.3%[23] Cash Flow and Investments - The net cash flow from operating activities improved to -¥63,019,837.85, a 58.60% reduction in cash outflow compared to -¥152,209,144.88 in the previous year[5] - Cash inflow from investment activities totaled 2,824,029.48 RMB, a significant decrease of 95.55% compared to the previous year[10] - The cash flow from operating activities showed a net outflow of CNY -63,019,837.85, an improvement from CNY -152,209,144.88 in the same quarter last year[24] - Investment activities resulted in a net cash outflow of CNY -128,451,669.47, compared to a net inflow of CNY 14,914,027.35 in the previous year[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,428,673,439.40, a slight increase of 0.20% from ¥6,415,749,761.32 at the end of the previous year[5] - Total liabilities decreased to CNY 2,828,967,325.17 from CNY 2,920,743,895.09, a reduction of 3.1%[19] - Non-current assets totaled CNY 3,373,165,881.10, slightly down from CNY 3,398,074,845.12, a decrease of 0.7%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,688[12] - The largest shareholder, Lin Jie, holds 35.07% of the shares, amounting to 122,028,474 shares, with 26,800,000 shares pledged[12] - The second-largest shareholder, Tu Yongjun, owns 16.41% of the shares, totaling 57,109,409 shares, with 16,700,000 shares pledged[12] Expenses - The company reported a significant increase in sales expenses, which rose by 37.94% to ¥13,214,486.14 compared to ¥9,580,078.07 in the previous year[9] - The financial expenses surged by 153.67% to ¥19,731,905.91, primarily due to increased interest expenses and foreign exchange losses[9] - The company experienced a 116.50% increase in taxes and surcharges, amounting to ¥7,202,386.16 compared to ¥3,326,808.96 in the same period last year[9] - The company incurred a total tax expense of CNY 25,872,286.97, which is an increase from CNY 14,505,480.46 in the same quarter last year[22] Inventory and Receivables - Accounts receivable rose to CNY 441,444,070.10, up from CNY 366,636,051.42, indicating an increase of 20.3%[17] - Inventory decreased to CNY 1,878,525,423.20 from CNY 2,017,183,241.46, a decline of 6.9%[17] Cash and Equivalents - Cash and cash equivalents increased to CNY 554,452,276.73 from CNY 476,981,463.45, representing a growth of 16.2%[17] - The company experienced a net increase in cash and cash equivalents of 107,745,677.84 RMB, representing an 80.17% increase year-on-year[10] - Cash and cash equivalents at the end of the period totaled CNY 377,973,652.28, up from CNY 367,275,932.06 at the end of the previous year[26]

Financial Performance - The company achieved operating revenue of CNY 2,666.68 million in 2022, a growth of 4.78% compared to CNY 2,545.01 million in 2021[4] - The net profit attributable to shareholders was CNY -118.95 million, a decline of 158.12% year-on-year, while the net profit excluding non-recurring gains and losses was CNY -83.09 million, down 151.68%[4] - The company's operating revenue for 2022 was ¥2,666,678,471.80, an increase of 4.78% compared to ¥2,545,009,527.24 in 2021[26] - The net profit attributable to shareholders was -¥118,952,557.99, a decrease of 158.12% from ¥204,676,095.23 in 2021[26] - The cash flow from operating activities was -¥48,699,787.90, an improvement of 81.43% compared to -¥262,230,037.31 in 2021[26] - The total assets at the end of 2022 were ¥6,415,749,761.32, representing a 10.60% increase from ¥5,800,601,655.48 at the end of 2021[26] - The basic earnings per share for 2022 was -¥0.34, a decline of 157.63% from ¥0.59 in 2021[26] Revenue Breakdown - CDMO business revenue fell to CNY 263.08 million, a decrease of 52.79% year-on-year, primarily due to reduced customer demand and fewer orders[5] - The revenue from generic raw materials and intermediates was ¥2,350,005,129.0, accounting for 88.12% of total revenue, with a year-on-year increase of 19.66%[73] - The revenue from CDMO raw materials and intermediates decreased by ¥263,079,986.81, a decline of 52.79%, primarily due to reduced customer demand[75] - The revenue from formulations increased by ¥33,968,396.04, a significant rise of 754.85%, attributed to an increase in approved products and improved marketing channels[75] Inventory and Production - The company recognized inventory impairment losses of CNY 96.47 million based on the lower of cost and net realizable value principle[5] - The inventory of generic raw materials and intermediates increased by 37.90%, mainly due to expanded production capacity and longer production processes[79] - Inventory increased by 80.68% year-on-year, attributed to order shipment delays and early stockpiling for Q1 2023[80] Research and Development - R&D investment amounted to CNY 15,215.88 million, a 43.49% increase compared to the previous year, with a compound annual growth rate of 41.65% over the past three years[69] - The R&D investment for formulation business in 2022 was CNY 153 million, with 6 new drug approvals obtained, indicating strong development capabilities[3] - The company has established three R&D centers with a total area of approximately 8,000 square meters and employs around 280 R&D personnel, forming a comprehensive innovation system[57] Market and Competitive Position - The global pharmaceutical market size reached $1,424 billion in 2021, with a projected growth rate of 3-6% from 2022 to 2026[38] - The global biopharmaceutical R&D expenditure reached $198 billion in 2020, expected to grow at a CAGR of 4.2% to $254 billion by 2026[39] - The company is one of the largest producers of sartans, with a diverse product range including antiviral and anti-asthma raw materials, and has established long-term partnerships with major global pharmaceutical companies[42] Corporate Governance - The company held five board meetings during the reporting period, all convened by the chairman[134] - The board consists of 7 members, including 3 independent directors, complying with relevant laws and regulations[133] - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management[134] - The company maintains independent operations in assets, personnel, finance, and business, ensuring no reliance on controlling shareholders[136] Environmental Compliance - Zhejiang Tianyu Pharmaceutical Co., Ltd. strictly complies with environmental protection laws, including the Environmental Protection Law and the Water Pollution Prevention Law[176] - The company has implemented measures to ensure that all emissions are within the regulatory limits, with no exceedances reported for various pollutants[178] - The total investment in environmental protection for the year 2022 amounted to 318 million yuan, including fixed asset investments related to environmental protection[186] Future Outlook - The company aims to achieve a revenue target of 250 million for the next fiscal year, representing a projected growth of 35%[143] - Future expansion plans include increasing production capacity while maintaining strict adherence to environmental standards[178] - The company is exploring potential mergers and acquisitions to enhance its market position and operational efficiency[178]

PAGE3 / NUMPAGES3 证券代码：300702 证券简称：天宇股份 浙江天宇药业股份有限公司 投资者关系活动记录表 编号：2020-002 | --- | --- | --- | |--------------------|-------------------------|--------------------------------------------------------------| | | | | | 投资者关系活动类别 | | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场 □其他 | | | 参会单位名称及 | | 证券研究所医药研究员、机构研究员 | | 人员 | | | | 时间 | 2020 年 6 月 10 | 日 | | 地点 | 公司会议室 | | | 上市公司接待人员 | | 董事会秘书、财务总监 王艳 证券事务代表 杨鹏、姜露露 | | 投资者关系活动主要 | | 第一部分：董事会秘书王艳女士总结 2019 年及 2020 年第 | | 内容介绍 | 一季度业绩概况 | ...

PAGE2 / NUMPAGES3 证券代码：300702 证券简称：天宇股份 浙江天宇药业股份有限公司 投资者关系活动记录表 编号：2017-001 | --- | --- | --- | |--------------------|-----------------------|----------------------------------------------------------| | | | | | 投资者关系活动类别 | | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场 □其他 | | | 参会单位名称及 | 中泰证券 - | 祝嘉琦 富国基金-姜恩铸 | | 人员姓名 | | 润晖投资-平晓川 兴证资产管理-毛泓洋 | | | 星石投资 - | 方磊 中国人寿资产管理 - 赵文龙 | | 时间 | 2017 年 11 月 | 16 日 | | 地点 | 公司四楼会议室 | | | 上市公司接待人员 | 董事长、总经理 屠勇军 | 董事会秘书、财务总监 王艳 | | 投资者关系活动主要 | 1 、 ...

证券代码：300702 证券简称：天宇股份 浙江天宇药业股份有限公司 投资者关系活动记录表 编号：2021-001 | --- | --- | --- | --- | |--------------------|------------------------------------------------|---------------------------------------------------------------|----------------------| | 投资者关系活动类别 | 特定对象调研 \n□新闻发布会 □路演活动 \n□现场 | □分析师会议 \n□媒体采访 □业绩说明会 \n□其他 | | | | 诺安基金 高毅资产 | 兴全基金 万家基金 | 信达澳银基金 | | | 毕盛投资 财通自营 | 诚旸投资 淳厚基金 | 丹羿投资 德邦 | | | 自营 东方港湾 | 东海证券自营 沣京资本 | 复胜资产 格林 | | | 基金 光大自营 | 广发资管 广州金控 和谐汇一 | 红土创新 | | | 基金 泓澄投资 | 华富基金 华泰柏瑞基金 | 华泰资管 华银 | | 参会 ...

证券代码：300702 证券简称：天宇股份 浙江天宇药业股份有限公司 投资者关系活动记录表 编号：2021-005 | --- | --- | --- | |--------------------|--------------------------------|------------------------------------------------------------| | | | | | | 特定对象调研 | □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | □现场 | □其他 | | 参会单位名称 | 券商医药研究员及机构研究员 | | | 时间 | 2021 年 11 月 9 日 | | | 地点 公司会议室 | | | | 上市公司接待人员 | 董事会秘书 王艳 | | | | 证券事务代表 杨鹏、姜露露 | | | | 条线情况 （一）沙坦原料药业务 | 第一部分：董事会秘书王艳女士总结近期公司各业务 | | | | | | | | 受上游原材料涨价等因素影响，公司近期沙坦原料药订单报价 | | | | ...